Robert Sebra | Mount Sinai

Biography

Research Topics

Biomedical Informatics, Cancer, Cancer Genetics, Epigenetics, Gene Expressions, Genetics, Infectious Disease, Molecular Biology, RNA, RNA Splicing & Processing, Stem Cells, Technology & Innovation, Translational Research

Multi-Disciplinary Training Area

Genetics and Genomic Sciences [GGS]

Publications

225

Publications

Selected Publications

Tracking HIV persistence across T cell lineages during early ART-treated HIV-1-infection using a reservoir-marking humanized mouse model. Namita Satija, Foramben Patel, Gerrit Schmidt, Donald V. Doanman, Manav Kapoor, Annalena La Porte, Ying Chih Wang, Kenneth M. Law, Anthony M. Esposito, Kimaada Allette, Kristin G. Beaumont, Robert P. Sebra, Benjamin K. Chen. Nature Communications

Oncofetal reprogramming drives phenotypic plasticity in WNT-dependent colorectal cancer. Slim Mzoughi, Megan Schwarz, Xuedi Wang, Deniz Demircioglu, Gulay Ulukaya, Kevin Mohammed, Habiba Zorgati, Denis Torre, Lewis E. Tomalin, Federico Di Tullio, Carlos Company, Yuliia Dramaretska, Marc Leushacke, Bruno Giotti, Tamsin R.M. Lannagan, Daniel Lozano-Ojalvo, Panagiotis Karras, Peter B. Vermeulen, Dan Hasson, Robert Sebra, Alexander M. Tsankov, Owen J. Sansom, Jean Christophe Marine, Nick Barker, Gaetano Gargiulo, Ernesto Guccione. Nature Genetics

An integrated approach for the accurate detection of HERV-K HML-2 transcription and protein synthesis. Charles Gleason, Sandra N. Terry, Matthew M. Hernandez, Samson Jacob, David Fenyo, Jeffrey R. Johnson, Gintaras Deikus, Nancy Francoeur, Aana Hahn, Robert Sebra, Dmitriy Zamarin, Henrik Molina, Viviana Simon, Lubbertus C.F. Mulder. Nucleic Acids Research

View All Publications

Office Locations

Icahn (East) Building Floor 14 Room 14-20E

1425 Madison Ave

New York, NY 10029

332-243-0721

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Sebra during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

Panacent Bio

Founder/Co-Founder/Partner

Panacent Bio

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Sebra during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

Panacent Bio

Founder/Co-Founder/Partner

Panacent Bio

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.